Goodwin and KPMG will host our 7th Annual Symposium held during the 44th Annual J.P. Morgan Healthcare Conference week.
Transactions to Transformations in Life Sciences and Healthcare of the Future
In today’s market, M&A and strategic transactions are increasingly critical to sustaining innovation and fueling growth for life sciences and healthcare companies. This year’s symposium will spotlight how industry leaders are leveraging dealmaking—not just as a response to capital constraints, but as a catalyst to advance pipelines, strengthen balance sheets, and position for long-term success.
Through candid discussions and actionable insights, we’ll explore both the art and the mechanics of end-to-end M&A, where the integration of the target is just as important as initial target diligence, the evolving financing landscape, creative partnering strategies, and the role of consolidation in shaping the next era of life sciences and healthcare.
Agenda
Begin the Symposium with a warm welcome on behalf of our Life Sciences group and KPMG.
An intimate conversation on how AI is reshaping discovery, clinical development, and deal activity.
A discussion on how different investor types – across PE, VC, and corporations – are approaching the sector, including insight into how investors are navigating risk, identifying scalable opportunities, and positioning for growth in a market that continues to evolve rapidly.
A tactical conversation on the realities of what works, what doesn’t, and how to cut through the gloss to build the strongest foundation for growth despite a complex, competitive, and compressed life sciences deal environment.
A close look at the Delaware rulings, commercial reasonable efforts, and implications for transactions.
A look at trends in China-related and cross-border deals with industry leaders, including the latest on BIOSECURE.
A discussion on structured financing, royalty financing, follow on offerings and ATMs, Debt & PIPEs, and investor sentiment and governance.
Close the day with our reception and connect with us, KPMG, and attendees.
Featured Insights
How the Trump Administration Could Reshape Regulation in the Life Sciences Sector
Life Sciences M&A Boom and Other Trends to Watch in 2025
Six Hot Trends in Life Sciences for 2025
Learn More about Life Sciences and Healthcare at Goodwin
Life Sciences Practice
Our Life Sciences practice is uniquely positioned to partner with innovators and investors operating in a fast-moving, technology-driven environment. We work with life sciences companies throughout the corporate lifecycle, as well as with investors, banks, and others in the life sciences ecosystem.
Life Sciences Perspectives Blog
Our Life Sciences Perspectives blog is a resource specifically aimed at addressing your most frequent and pressing issues in this dynamic industry. We provide the insights you need most, including developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies.
Integrated Healthcare Practice
Health Headlines
Related Content & Attendees
- AlertDecember 22, 2025
CMS Releases MFN Drug Pricing Models for Medicare Parts B and D and Medicaid Amid Trump Administration’s Push for Direct-to-Consumer Strategy
- Forces of Law 2026December 10, 2025
How Medicaid Cuts Could Reshape the Business of Health
- Forces of Law 2026December 10, 2025
AI Drug Discovery Tests the Limits of Patent Law
- Forces of Law 2026December 10, 2025
Mass Arbitration: The Risk Lurking in Consumer Agreements
- Health HeadlinesNovember 28, 2025
Health Headlines: November 2025
- Health HeadlinesOctober 31, 2025
Health Headlines: October 2025
- AlertOctober 13, 2025
California Governor Signs AB 1415, Extending Healthcare Transaction Oversight to MSOs
- AlertOctober 17, 2025
Watch Out Section 101, the USPTO Has a New Sheriff in Town
